Arvinas, Inc.

In March 2018, Deerfield invested in Arvinas, LLC., a preclinical biotechnology company based on the science developed from the lab of Craig Crews, Ph.D., the Lewis B. Cullman Professor of Molecular, Cellular and Developmental Biology at Yale University. Arvinas is focused on developing a new class of drugs, small molecules called PROTACs, that are aimed at degrading disease-causing cellular proteins through proteolysis.